Fatty liver has become a worldwide epidemic. The FibroScan is a clinically proven, safe, non-invasive way to identify a fatty liver. With ultrasound waves we will measure a 3 cm2 area of the liver, calculating fat and liver stiffness. As fat accumulates in the liver it can cause cell damage and inflammation which stiffens the liver. Increased stiffness can turn into liver disease, which can lead to liver failure. With the FibroScan we can identify the amount of fat you may have in your liver and the degree of stiffness, providing you with detailed information about your risk factors.
There are two types of Fatty Liver, Alcoholic and non-alcoholic. A Fatty liver is when more than 5% of your liver is fat. There is currently an epidemic of non-alcoholic fatty liver disease (NAFLD) in North America. Between 70%-92 % of people who are carrying too much body fat have fatty liver.
Non-Alcoholic Fatty Liver is very common, affecting more than 30% of North Americans. If you have NAFLD you may be at a greater risk of cardiovascular mortality and morbidity. NAFLD can lead to Non-alcoholic Steatohepatitis (NASH) which is fatty liver with inflammation and cell damage. NASH can lead to cirrhosis of the liver, which is when scar tissue gradually replaces healthy tissue. Cirrhosis is not reversible.
Alcoholic Fatty Liver is caused by over consumption of alcohol. You may be at risk if you are a woman and regularly drink more than 2 drinks per day or more than 10 drinks total per week. If you are a man, and drink more than 3 drinks per day, or more than 15 drinks per week.
FibroScan is a non-invasive technology that quickly provides a quantitative assessment of liver stiffness and fat. The FibroScan provides much more detail than traditional ultrasound. The traditional liver ultrasound gives no information about the severity of liver scarring except in very extreme circumstances (i.e. advanced cirrhosis). The FibroScan is much more sensitive than ultrasound and can identify less severe scarring, which allows you to start the appropriate treatment before the disease becomes too advanced. In addition, the FibroScan can efficiently rule out the need for further assessment, such as a painful liver biopsy.
A 5-7% decrease in body weight can be associated with a reduction in liver fat and inflammation.